Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247655 | 0.92 | PIK3CD (0.58) | PIK3CDPIK3CA | |
| SCHEMBL248533 | 0.90 | PIK3CD (0.54) | PIK3CDPIK3CARAF1BRAFATR | |
| SCHEMBL248643 | 0.90 | PIK3CD (0.52) | PIK3CDPIK3CARAF1BRAFATR | |
| SCHEMBL247333 | 0.86 | PIK3CD (0.52) | PIK3CDPIK3CARAF1BRAFATR | |
| SCHEMBL249148 | 0.85 | PIK3CD (0.55) | PIK3CDPIK3CA | |
| SCHEMBL247692 | 0.85 | PIK3CD (0.59) | PIK3CDPIK3CA | |
| SCHEMBL249157 | 0.84 | PIK3CD (0.60) | PIK3CDPIK3CAATR | |
| SCHEMBL2712239 | 0.83 | PIK3CD (0.59) | PIK3CDPIK3CAATRKCNH2 | |
| SCHEMBL249029 | 0.83 | PIK3CD (0.52) | PIK3CDPIK3CAATRLRRK2 | |
| SCHEMBL247235 | 0.83 | PIK3CD (0.64) | PIK3CDPIK3CAATRLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CD 24/4885PIK3CA 28/4885TGFBR1 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.